Drug Trial Radar · NCT07145229
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
479
Actual
Start
Aug 26, 2025
Primary completion
Jul 14, 2026
Study completion Aug 11, 2026
Sponsor
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.
Conditions
- Acute Gouty Arthritis
- Gout Flare
- Gout Flares
- Acute Gout Flare
Interventions
ABP-745 Dose ADrug
ABP-745 Dose A + Colchicine placebo - tablets (PO)
ABP-745 Dose BDrug
ABP-745 Dose B + Colchicine placebo - tablets (PO)
ColchicineDrug
ABP-745 placebo + Colchicine - tablets (PO)
PlaceboDrug
ABP-745 placebo + Colchicine placebo - tablets (PO)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Visual Analog Scale (VAS) pain score of the target jointTime frame: 24 hours post the first dose of study drug
Locations
38 sites in 3 countries. Site status is shown where the registry gives one.
Onyx Clinical Research
Peoria, Arizona
Exinia Research
La Mesa, California
Evergreen Clinical Trial
Norcross, Georgia
Bioluminux Clinical Research
Naperville, Illinois
Exinia Research
Des Moines, Iowa
Northshore Research Associates
Alexandria, Louisiana
DelRicht Research
Baton Rouge, Louisiana
DelRicht Research
New Orleans, Louisiana
Interphase Clinical Trials
Lutherville, Maryland
DelRicht Research Gulfport
Gulfport, Mississippi
Albuquerque Clinical Trials, Inc.
Albuquerque, New Mexico
West Clinical Research
Morehead City, North Carolina
DelRicht Research
Tulsa, Oklahoma
Premier Family Physicians
Austin, Texas
Emeritus Sydney
Botany, New South Wales, Australia
Canopy Clinical Research Northern Beaches
Brookvale, New South Wales, Australia
Novatrials
Kotara, New South Wales, Australia
Genesis Research Services
Newcastle, New South Wales, Australia
Emeritus Melbourne
Camberwell, Victoria, Australia
Canopy Clinical Research Altona North
North Altona, Victoria, Australia
Peking University Third hospital
Beijing, Beijing Municipality, China
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
The second affiliated hospital of guangxi medical university
Nanning, Guangxi, China
Hebei Petro China Central Hospital
Langfang, Hebei, China
Wuhan UHospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Xiangtan Central Hospital
Xiangtan, Hunan, China
Xiangya Hospital Zhuzhou Central South University
Zhuzhou, Hunan, China
Huai'an First People's Hospital
Huai'an, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Zaozhuang Municipal Hospital
Zaozhuang, Shandong, China
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Linfen Central hospital
Linfen, Shanxi, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
Shaanxi Provincial People's Hospital
Xi’an, Shanxi, China
Xi'an Daxing Hospital
Xi’an, Shanxi, China
Chengdu Fifth People's Hospital
Chengdu, Sichuan, China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Wenzhou People's Hospital
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.